- Aethlon Medical (NASDAQ:AEMD) initiated with Buy rating and $3 (209% upside) price target by H.C. Wainwright.
- Aimmune Therapeutics (NASDAQ:AIMT) initiated with Buy rating and $60 (71% upside) price target by Roth Capital.
- Ablynx (NASDAQ:ABLX) initiated with Buy rating by Ladenburg Thalmann. Initiated with Outperform rating and $33 (57% upside) by Robert W. Baird.
- Innoviva (NASDAQ:INVA) initiated with Hold rating by Deutsche Bank (DE:DBKGn).
- Catabasis Pharmaceuticals (NASDAQ:CATB) upgraded to Buy with a $2.50 (54% upside) price target by Citigroup (NYSE:C).
- Kindred Healthcare (NYSE:KND) upgraded to Hold with a $7 (flat) price target by Stifel.
- Advanced Accelerator (NASDAQ:AAAP) downgraded to Neutral by JPMorgan (NYSE:JPM) after Novartis bid.
- Almost Family (NASDAQ:AFAM) downgraded to Sector Perform with a $62 (flat) price target by RBC.
- Cardinal Health (NYSE:CAH) downgraded to Underweight with a $51 (11% downside risk) price target by Morgan Stanley (NYSE:MS) on potential encroachment by Amazon (NASDAQ:AMZN). Shares are down 3% premarket.
- Ligand Pharmaceuticals (NASDAQ:LGND) downgraded to Sell with a $105 (25% downside risk) price target by Deutsche Bank.
- Prothena (NASDAQ:PRTA) downgraded to Neutral by Wedbush.
- Source: Bloomberg
- Now read: Aimmune Therapeutics (AIMT) Presents At Jefferies 2017 London Healthcare Conference - Slideshow
Original article